Chronic Heart Failure Market and Forecast Analysis to 2024, Pharma Intelligence

Chronic Heart Failure Market and Forecast Analysis to 2024, Pharma Intelligence

  • January 2019 •
  • 421 pages •
  • Report ID: 5779837 •
  • Format: PDF
Disease Overview

Chronic heart failure (CHF) is a serious medical condition in which the heart is unable to adequately fill with and eject blood. CHF can result from functional abnormalities such as ventricular dysfunction or arrhythmias, but structural disorders of the heart muscle or valves are also common causes. While current therapies have helped to improve patient outcomes, CHF still remains a major public health issue and is associated with high mortality rates and a poor prognosis.

Market Snapshot

Increased use of Entresto and a full pipeline will revitalize the mature CHF market.
Novel CHF treatments have yet to alter prescribing practices from traditional ACE inhibitors and beta blockers.
CHF prevalence rises with age, with 55–84 years comprising three-quarters of all diagnosed prevalent cases in adults.
Entresto has overcome initial barriers to uptake and has the potential to change CHF treatment practices.
Despite a full pipeline it is unlikely that any candidates have the potential to significantly change treatment practices.